| Description |
MDX-1342 is a fully human monoclonal antibody (HuMAb) of targeting CD19-membrane receptor. MDX-1342 can specifically bind to human CD19 antigen with high affinity and has antibody-dependent cellular cytotoxicity (ADCC) effect. MDX-1342 can be used for the research of B-lymphocyte malignancies and autoimmune[1].
|
| Related Catalog |
|
| Target |
EC50 for binding activity: 0.34 μg/mL(Ramos cells); 0.47 μg/mL(Raji cells); 0.74 μg/mL(ARH-77 cells); 0.37 μg/mL(FcyRIIIa-Val158 transfected cells); 1.18 μg/mL(FcyRIIIaPhe158 transfected cells)[1]
|
| In Vitro |
MDX-1342 (0-100 μg/mL; 30 min) shows binding activity for Ramos, Raji, and ARH-77 cells with EC50 values of 0.34, 0.47, and 0.74 μg/mL, respectively[1]. MDX-1342 (0-100 μg/mL; 30 min) shows binding activity for FcyRIIIa-Val158 and FcyRIIIaPhe158 transfected cells with EC50 values of 0.37 and 1.18 μg/mL, respectively[1]. MDX-1342 (0-100 μg/mL) has robust antibody-dependent cellular cytotoxicity (ADCC) with an average EC50 value of 0.01-0.02 ug/mL[1]. MDX-1342 (0-100 μg/mL) mediates dose-dependent phagocytosis of ARH-77 cells by macrophages[1]. Cell Viability Assay[1] Cell Line: human CD19-transfected CHO cells Concentration: 0-100 μg/mL Incubation Time: 30 min Result: Exhibited increased affinity for FcyRIlla-Phe158 and FcyRIlla-Val158 receptors.
|
| In Vivo |
MDX-1342 (i.v.; 0.03, 0.3, 3 and 30 mg/kg; 200 μL) shows dose-dependent improvement in survival using a murine B-cell lymphoma model[1]. MDX-1342 (i.v.; 0.1 or 1 mg/kg; single) has low nanomolar binding to cynomolgus monkey CD19, increases affinity for cynomolgus monkey FcyRllla and reveals potent B-cell depletion in vivo[1]. Animal Model: cynomolgus monkey[1] Dosage: 0.1 or 1 mg/kg Administration: i.v., single Result: Showed B-cell depletion in the cynomolgus monkey. Animal Model: Ramos systemic tumor xenograft model(SCID mice)[1] Dosage: 0.03, 0.3, 3 and 30 mg/kg Administration: i.v., 200 μL Result: Showed dose-dependent improvement in survival.
|
| References |
[1]. Pina M Cardarelli, et al. A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunol Immunother. 2010 Feb;59(2):257-65.
|
